FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
September 28 2018 - 5:44PM
Dow Jones News
By Stephen Nakrosis
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi said Friday
the U.S. Food and Drug Administration gave its approval to Libtayo
for the treatment of patients with metastatic cutaneous squamous
cell carcinoma, or CSCC.
The companies said CSCC is the second most common skin cancer in
the U.S.
Regeneron and Sanofi Genzyme, the specialty care global business
unit of Sanofi, will market Libtayo jointly in the U.S.
Shares of Regeneron, which closed Friday trading down 0.48% at
$404.04, were up slightly in after-hours trading, gaining 1.48% to
$410.00.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2018 17:29 ET (21:29 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
